CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of chronic lymphocytic leukemia.
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with chronic lymphocytic leukemia.
  
  LEARNING OBJECTIVES

  • Discuss available Phase III data demonstrating the superior efficacy and safety of Bruton tyrosine kinase (BTK) inhibition compared to standard chemoimmunotherapy as first-line therapy for CLL, and use this information to counsel patients regarding available front-line options.
  • Assess the FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and explain to patients the risks and potential benefits of time-limited therapy.
  • Appraise available Phase III data documenting the comparative efficacy and tolerability of first- and second-generation BTK inhibitors, and consider the implications of these findings for clinical decision-making for patients with newly diagnosed or previously treated CLL.
  • Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented data documenting the safety and efficacy of this strategy for patients with newly diagnosed CLL.
  • Analyze how patient age, performance status, prior therapeutic exposure and other biologic and disease-related factors affect the selection and sequencing of therapy for relapsed/refractory CLL, and provide corresponding education to patients.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies for CLL.

  ACCREDITATION STATEMENT
  Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  
  CREDIT DESIGNATION STATEMENT
  NCPD credit is no longer available for this issue
  
  ONCC/ILNA CERTIFICATION INFORMATION
  NCPD credit is no longer available for this issue
  
  FOR SUCCESSFUL COMPLETION
  Video Program: This NCPD activity consists of a video component.
  NCPD credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY —The following faculty reported relevant financial relationships with ineligible entities:
  
  John N Allan, MD
  Associate Professor of Clinical Medicine
  Weill Cornell Medicine
  New York, New York
  
  Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Epizyme Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Contracted Research: BeiGene Ltd, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, TG Therapeutics Inc; Nonpromotional Disease State Awareness Speaking: AbbVie Inc, BeiGene Ltd, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company.
  
  Jacqueline Broadway-Duren, PhD, DNP, APRN, FNP-BC
  Family Nurse Practitioner
  Department of Leukemia
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Roles: AbbVie Inc, Pharmacyclics LLC, an AbbVie Company.
  
  Corinne Hoffman, MS, APRN-CNP, AOCNP
  Nurse Practitioner, Hematology
  The James
  The Ohio State University Comprehensive Cancer Center
  The Ohio State University Wexner Medical Center
  Columbus, Ohio
  
  Advisory Board: BeiGene Ltd, Pharmacyclics LLC, an AbbVie Company.
  
  Adam S Kittai, MD
  Assistant Professor
  Division of Hematology
  The James
  The Ohio State University Comprehensive Cancer Center
  Columbus, Ohio
  
  Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Janssen Biotech Inc, Kite, A Gilead Company, Lilly; Consulting Agreement: AbbVie Inc; Contracted Research: AstraZeneca Pharmaceuticals LP; Speakers Bureau: BeiGene Ltd.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.
  
  Release date: May 2023
  Expiration date: May 2024
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.